Drug intelligence / Profile preview

LAMA3 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
In Vitro (typical), Other Routes Depend On Delivery Method (e.g., Local Or Systemic Administration Expected In Therapeutic Settings, But None Proven In Clinical Use)
01

Overview

LAMA3 siRNA is a small interfering RNA (siRNA) molecule designed to specifically silence the expression of the LAMA3 gene, which encodes the laminin subunit alpha 3, a component of extracellular matrix proteins critical for basement membrane structure, cell adhesion, proliferation, and migration. LAMA3 siRNA mediates post-transcriptional gene silencing by targeting LAMA3 mRNA, leading to its degradation and reduced LAMA3 protein production. Experimental studies, particularly in cholangiocarcinoma (CCA) cell lines, demonstrate that LAMA3 siRNA efficiently downregulates LAMA3A mRNA, resulting in reduced cancer cell proliferation, inhibition of cell adhesion and migration, and reversion of epithelial-to-mesenchymal transition (EMT) phenotypes. These findings suggest that LAMA3 siRNA has potential therapeutic value as an investigational cancer therapy and as a tool for functional genomics research[1][2][3][6][9][11].

Other names
LAMA3 siRNALAMA-3 siRNALAMA 3 siRNA
02

Targets

LAMA3 (Laminin subunit alpha-3)

Beyond the preview

Go deeper on LAMA3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAMA3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call